Lymphomatoid papulosis
The lymphomatoid papulosis is a benign skin Affected by T-cell pseudolymphoma.
Symptomatic lesions show itself in the form of papules. This can take many different forms: in color from pink to dark brown, sometimes with the formation of necrosis, numerically to hundreds of one to. The lesions usually heal by itself within a few weeks again. However, a small scar remains back regularly. In contrast to other cutaneous T -cell lymphoma, the CD30 surface molecule is at lymphomatoid papulosis expressed ( CD30 ).
Lymphomatoid papulosis which was first described in 1968 by WL Macaulay caused as a disease that " histologically malignant and clinically benign lesions of the skin ." Meanwhile three subtypes (A-C ) can be distinguished lymphomatoid papulosis, the distinction of other subtypes is the subject of current research.
Overall, it is very rare condition. One starts with an incidence of approximately 1.2 to 1.9 cases per 1,000,000 people. The resulting very low awareness of the disease and the most harmless course presumably lead to a significant number of incorrect diagnosed cases.
The differential diagnosis mycosis fungoides is to delineate, with a parallel occurrence is possible; further chickenpox, syphilis, allergic vasculitis and much more
The prognosis is very good. Complete remissions are seen even under long-term follow-up. In a single-center retrospective study observed the 299 patients with cutaneous lymphoma over the period from January 1980 to December 2005, the best 5 - year survival rate of 100 % was determined for lymphomatoid papulosis. On the other hand, the risk of a disease from a malignant lymphoma seems slightly increased. A study of Bekkenk et al with 118 patients reported a progression after 10 years in 4%.
A curative treatment does not currently exist. The resulting lesions can be combated with a PUVA treatment. Furthermore, be used with limited success corticosteroids. Topical treatment will be carried out experiments with different active ingredients, among others, the drugs imiquimod and tacrolimus. In severe cases, recurrent systemic treatment using low-dose methotrexate to be considered.